– Reuters
Maxim Group Downgrades Aridis Pharmaceuticals to Hold
Maxim Group analyst Jason McCarthy downgrades Aridis Pharmaceuticals (NASDAQ:ARDS) from Buy to Hold.
Related Posts
Autolus Therapeutics’ Leukemia Trial Meets Primary Goal Of Remission Rate, Shares Fall After $150M Capital Raise
Autolus Therapeutics plc’s (NASDAQ:AUTL) Phase 2 pivotal FELIX trial of obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) adult Acute Lymphoblastic…
What’s Going On With SNDL Stock?
SNDL Inc. (NASDAQ: SNDL) shares are trading higher on Wednesday. The stock appears to be moving in sympathy with Tilray Brands, Inc. (NASDAQ: TLRY), which surged on
What’s Going On With SoundHound AI Stock?
SoundHound shares began surging shortly after the market close on Wednesday as traders circled a new 13-F filing from Nvidia in which the company disclosed a 1.73 million share stake in SoundHound.